Eli Lilly and CompanyNYSE: LLY
Health Care · Pharmaceuticals
$964.50
+3.20%
Vol: 6.2M
Research Digest
Friday, May 1, 2026
Eli Lilly blows past Q1 estimates with 56% revenue surge driven by Mounjaro and Zepbound, raises full-year guidance by $2B
Eli Lilly reported Q1 adjusted EPS of $8.55 vs. $6.66 expected and revenue of $19.80B vs. $17.62B expected, up 56% YoY. Mounjaro and Zepbound combined generated $12.8B in sales. Company raised full-year guidance to $82-85B (from $80-83B) and guided Q2 Foundayo launch. FDA proposed rule protecting key drugs from compounding. Stock surged 10.54% on earnings beat.
Previous Market Intelligence
13 daysApr 30Eli Lilly crushes Q1 2026 earnings with 56% revenue growth and raises full-year guidance by $2 billionPositive▶
Eli Lilly reported exceptional Q1 2026 results with revenue of $19.80 billion, up 56% year-over-year, and EPS of $8.55 beating estimates of $7.06. The company raised 2026 revenue guidance to $82-85 billion (from $80-83 billion) driven by GLP-1 drug dominance with 60.1% market share in obesity/diabetes market. The FDA approved Foundayo (orforglipron), the first GLP-1 pill approved for obesity. Strategic acquisitions include Orna Therapeutics, Centessa Pharmaceuticals, and Ajax Therapeutics. Key risk: intense competition from Novo Nordisk, which holds 39.4% GLP-1 market share.
Apr 29Eli Lilly acquires Ajax Therapeutics for $2.3B as earnings due April 30; shares down 2.39% on sector pressureMixed▶
Eli Lilly agreed to acquire Ajax Therapeutics in a $2.3B transaction, its second oncology deal this month, to advance JAK inhibitor treatments. Company reports Q1 earnings tomorrow with expected 36.8% revenue growth. Shares fell 2.39% amid selling pressure. Revenue growth remains robust at 43% in Q4 2025 to $19.3B. Analyst consensus is Strong Buy with $1,218.84 average target.
Apr 16Eli Lilly Foundayo weight-loss pill launches commercially April 9 with FDA approval and 60% U.S. market share, but FDA requests additional post-marketing safety dataMixed▶
Eli Lilly achieved FDA approval for Foundayo (orforglipron), an oral GLP-1 obesity drug, with retail pharmacy distribution beginning April 9, 2026. The drug showed an average weight loss of 27.3 pounds (12.4%) at the highest dose. Copays start at $25/month, with self-pay from $149/month. However, the FDA requested post-marketing studies assessing liver injury, cardiovascular events, and delayed gastric emptying. Eli Lilly holds 60% U.S. weight-loss market share versus Novo Nordisk 39%. The company also agreed to acquire Centessa Pharmaceuticals for up to $47 per share, expanding neuroscience footprint. Earnings due April 30.
Apr 15Eli Lilly GLP-1 pill Foundayo achieved FDA approval with strong global expansion plans, while Phase 3 leukemia drug trial met primary endpointsPositive▶
Eli Lilly received FDA approval on April 1 for Foundayo (orforglipron), its oral GLP-1 pill for weight loss. The company announced positive Phase 3 BRUIN CLL-322 trial results for Jaypirca. Lilly is investing $3 billion in China and $125 million in Japan for GLP-1 production. A $2.75 billion partnership with Insilico Medicine will bring AI-developed drugs to global markets.
Apr 14Eli Lilly Jaypirca meets Phase 3 endpoint in blood cancer; Foundayo FDA-approved obesity pill gaining tractionPositive▶
Positive Phase 3 BRUIN CLL-322 trial results for Jaypirca. FDA-approved Foundayo launching broadly. Analysts rate Strong Buy with $1,217.79 PT.
Apr 13Foundayo oral GLP-1 obesity pill FDA approved and launched; Centessa Pharma acquisition announced for $6.3BPositive▶
Eli Lilly secured FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 for obesity, with retail pharmacy shipping beginning April 9, 2026. The company showed average weight loss of 27.3 pounds (12.4%) at highest dose. Separately, Lilly agreed to acquire Centessa Pharmaceuticals for $38 per share ($6.3B equity value), expanding its neuroscience footprint. Market expansion initiatives underway via LifeMD and multiple retail partners.
Apr 10Eli Lilly's Foundayo oral GLP-1 pill approved by FDA on April 1 with retail pharmacy shipping beginning April 9.Positive▶
FDA approved Foundayo (orforglipron), Eli Lilly's oral GLP-1 weight-loss medication on April 1, 2026, with retail pharmacy shipping beginning April 9. Foundayo is the second oral GLP-1 to market after Novo Nordisk's Wegovy. Average weight loss of 27.3 pounds (12.4%) at highest dose. Commercial copays start at $25/month. Eli Lilly agreed to acquire Centessa Pharmaceuticals for $38/share plus CVR. Q1 earnings expected April 30 with analysts predicting EPS of $7.55 (up 126.1% YoY).
Apr 9FDA approval of Foundayo weight-loss pill drives Lilly stock higher as CEO signals production readinessPositive▶
Eli Lilly received FDA approval for Foundayo, an oral obesity treatment, with CEO Dave Ricks confirming the company is ready to scale production. Guggenheim maintains bullish stance ahead of Q1 results. The stock rose 6.5% on approval news, though faces headwinds from Zepbound price cuts and slower guidance. Analysts project strong fundamentals with an average 12-month target of $1,200.60, up 25% from current price. Near-term challenges include competitive pressure from Novo Nordisk.
Apr 8FDA approves Eli Lilly oral weight-loss pill Foundayo; CEO ready to scale production globally.Positive▶
Eli Lilly received FDA approval for Foundayo, an oral GLP-1 weight-loss medicine on April 1. CEO Dave Ricks confirmed company is ready to scale production globally. Positions Lilly to compete in growing weight-loss drug market. Strong Buy consensus among 19 analysts with average price target of $1247.38 (31.53% upside). Stock rose 6.5% post-approval.
Apr 7FDA approves Eli Lilly's Foundayo (orforglipron) GLP-1 pill; Lilly acquires Centessa Pharma for $7.8B to expand neurosciencePositive▶
Eli Lilly won FDA approval for Foundayo (orforglipron), the first once-daily oral GLP-1 pill for obesity that can be taken anytime without food/water restrictions. Shipments begin this week; widespread pharmacy and telehealth availability expected. Stock surged 6.5% last week. Company acquiring Centessa Pharmaceuticals for $7.8 billion to expand neuroscience portfolio. FY2025 revenue $65.18B (+44.7% YoY) driven by GLP-1 franchises Mounjaro and Zepbound commanding 60% weight-loss market share. FY2026 guidance $80-83B. Analyst breakdown: 24 Buy, 6 Hold, 1 Sell. Lilly also announced >$50B U.S. manufacturing investment expansion since 2020.
Apr 6Eli Lilly receives FDA approval for Foundayo oral GLP-1 pill; launching April 6 with once-daily dosing.Positive▶
Eli Lilly received FDA approval for Foundayo (orforglipron), once-daily oral GLP-1 weight-loss pill with no food/water restrictions. Shipping began April 6 via LillyDirect. Commercial copays start at $25/month. Medicare Part D access may begin July 1. Stock jumped 4.7-6.5% post-approval. $7.8B Centessa acquisition diversifies into neuroscience. 20 Strong Buy ratings, $1,200.60 target.
Apr 3FDA approves Eli Lilly's oral obesity drug Foundayo with strong clinical results and April 6 launch; company also acquiring Centessa for $7.8 billion.Positive▶
Eli Lilly received FDA approval for Foundayo (orforglipron), an oral GLP-1 medication for obesity, 50 days after filing under an expedited pilot program. Patients on the highest dose lost an average of 27.3 pounds (12.4% body weight) versus 2.2 pounds with placebo. The pill will launch April 6 through LillyDirect at $149/month or $25 with insurance. The $7.8 billion acquisition of Centessa broadens the pipeline into sleep-wake disorders. Stock rallied 5% Wednesday following approval but closed Thursday down 1.98% amid broader market pressure.
Apr 1Eli Lilly to acquire Centessa Pharmaceuticals for up to $7.8 billion to bolster sleep disorder drug pipeline; FDA decision on oral weight loss pill Orforglipron expected April 10.Positive▶
Eli Lilly announced a major acquisition of Centessa Pharmaceuticals for $6.3 billion upfront plus $1.5 billion in milestone payments, targeting narcolepsy and excessive drowsiness treatments. The company beat Q4 2025 earnings expectations with $7.54 EPS versus consensus of $7.48, with revenue of $19.29 billion up 42.6% YoY. FY 2026 EPS guidance set at 33.5-35.0. A critical near-term catalyst is the FDA's April 10 decision on Orforglipron, Lilly's oral weight loss pill offering greater convenience than competitors. Earnings are scheduled for April 30, 2026.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $964.50 | +3.20% | +0.8% | 22.2x | 0.50 | $834.9B |
| JNJJOHNSON | $227.78 | -0.90% | -4.6% | 18.1x | 0.33 | $553.3B |
| MRKMERCK | $112.32 | +2.88% | -9.7% | 11.2x | 0.28 | $269.7B |
| PFEPFIZER | $26.37 | -1.25% | -4.1% | 9.5x | 0.39 | $151.9B |
| BMYBRISTOL | $58.19 | -3.97% | +2.1% | 9.9x | 0.27 | $123.7B |
| ZTSZOETIS | $114.35 | -0.54% | -2.8% | 15.2x | 0.97 | $48.5B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.